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4 times ($24,247 vs. $6,903). For the non-surgical group (N3177), however, the
total cost of all recurrences was slightly less than initial acute episode costs ($2478
vs. $2648). CONCLUSIONS: Costs associated with recurrent DV episodes are signif-
icant, with recurrences costing substantially more than initial acute episodes.
Among those with a recurrence, significant variation in costs among those with
and without surgical intervention exists.
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OBJECTIVES: Little is known about the overall burden of chronic hepatic diseases
(CHDs) for the health care third-payer, patients and their families. We performed a
Cost of Illness study named COME, to assess the societal burden (direct, indirect
and intangible costs) in patients with CHDs. The following results pertain to pa-
tients who received liver transplantation (LT). METHODS: The COME Study was a
naturalistic, multicenter, retrospective (time horizon: 6 months) work involving
1088 adult patients with CHDs. Costs were assessed from the societal perspective
and are reported as mean /patient-month (direct costs) and mean days lost from
work/study/usual activities per patient-month (loss of productivity). Patients’
Health Related Quality of Life was assessed with the EQ-5D questionnaire and is
reported as percentage of patientswith problems and asmeanSD visual analogue
scale (VAS) score. RESULTS: A total of 11.8% of the study sample had a LT. These
patients were 72.9% male, aged 19-72 (median57.5) years. Etiological agents re-
sponsible for LT were: HBV (36.2%), HCV (43.1%), HBV-HCV co-infection (3.4%),
other etiology (17.3%). Mean direct cost were 2628.8 €/patient-month. Hospitaliza-
tions contributed to 56.4% of costs, 40.2% generated from 11 patients who received
LT during the observational period. Treatment contributed to 39.5% of costs. Out-
patient contributed to 0.3% of costs. Nonmedical costs contributed to 3.7% of direct
costs. Three days/patient-month of productivity was lost by the patients and their
family caregivers. Thirty-four percent of patients reported problems in walking
about, 12.4% had problems with self-care, 42.1% had problems in doing usual ac-
tivities, 49.2% had pain or discomfort, and 40.2% had anxiety or depression. The
meanSD VAS was 69.120.5. CONCLUSIONS: High societal costs are generated
from having CHDs and in particular among patients with LT. The implementation
of efficient treatments aimed to reduce worsening of CHDs can help to improve
patients’ health and reduce societal costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases’ (CHDs) is little known. We
aimed to assess costs (direct, indirect and intangible) in patients with CHDs. The
following results pertain to patients with chronic Hepatitis C (HC).METHODS:We
conducted a naturalistic, multicenter, retrospective Cost-of-Illness study, named
COME. Costs occurring during the 6months before enrollment were assessed from
the societal perspective (i.e., NHS, patients and caregivers). Direct costs included
non medical (traveling/accommodation, formal caregiver payments) and medical
costs: conventional drug and unconventional treatment (e.g., homeopathy, herbal
medicines, vitamins, etc), hospitalization, outpatient medical visits and diagnostic
examinations. Loss of productivity was measured for patients and caregivers. Re-
sults are expressed as: €/patient-month (direct costs); days/patient-month (indi-
rect cost). Patients’ HRQoL was assessed with the EQ-5D questionnaire and is re-
ported as percentage of patients with problems and as meanSD visual analogue
scale (VAS) score. RESULTS:A total of 31.8% of the study sample (1088 patients) had
chronic HC. These patients were 54.6% male, aged 20-83 (median60.2) years.
Overall HC patients generatedmean direct costs corresponding to 233,68€/patient-
month. Treatment contributed to 71.1% of costs. Ribavirin-INF protocol was ad-
opted in 57.7% of patients. Hospitalizations contributed to 14.7% of costs and in-
volved 11.6% of the patients. Outpatient accesses contributed to 7.4% of costs and
involved 98% of the patients. Non medical costs contributed to 6.8% of direct costs
and involved 92.1% of the patients. Patients and their family caregivers lost on
average 0.7 days/patient-month of productivity. Twenty percent of patients re-
ported problems in walking about, 12.5% had problems with self-care, 25.4% had
problems in doing usual activities, 36.3% had pain/discomfort, and 44.7% had anx-
iety/depression. The meanSD VAS was 68.820.3. CONCLUSIONS: Chronic HC
generates high costs to the health care system. The use of efficient treatments is
necessary to reduce worsening of patients’ health, direct and indirect costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases (CHDs) is little known. We
aimed to assess social burden (direct, indirect and intangible cost) in patients with
CHDs. The following results pertain to patients with chronic Hepatitis B (HB).
METHODS: COME is a naturalistic, multicenter, retrospective cost of illness study.
Costs occurring during the 6 months before enrollment were assessed from the
societal perspective. Direct costs included nonmedical (traveling/accommodation,
caregiver payments) and medical costs: conventional (drug) and unconventional
treatment (e.g., homeopathy, vitamins, etc), hospitalization, outpatient medical
visits and diagnostic examinations. Loss of productivity wasmeasured for patients
and caregivers. Results are expressed as: €/patient-month (direct costs); days/pa-
tient-month (indirect costs). Patients’ HRQoL was assessed with the EQ-5D ques-
tionnaire and is reported as percentage of patientswith problems and asmeanSD
VAS score. RESULTS: Among 1088 adult patients enrolled, 221 had chronic HB
(20.3%). These patients were 69.7% male, aged 19-81(median56.1) years. Overall
HB patients generated mean direct costs corresponding to 308.1€/patient-month.
Treatment contributed to 76.9% of costs, involving 53.4% of the patients. In partic-
ular, 46.2% of patients were treated with antiviral drugs for systemic use (lamivu-
dine, ribavirin, etc). Hospitalizations contributed to 12.9% of costs and involved
9.0% of the patients. Outpatient accesses contributed to 5.4% of costs and involved
99.1% of the patients. Non medical costs contributed to 4.8% of direct costs and
involved 90.8% of the patients. Patients and their family caregivers lost on average
0.4 days/patient-month of productivity. As regardsHRQoL, patients reporting prob-
lems were: 24.4% of patients in walking about, 12.0% in self-care, 30.5% in usual
activities, 36.1% in pain/discomfort and 45.6% in anxiety/depression domain. The
meanSD VAS was 71.2520.72. CONCLUSIONS: Chronic HB generates high costs
to the healthcare system. The use of efficient treatments is necessary to reduce
worsening of patients’ health, direct and indirect costs.
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OBJECTIVES:We assessed changes in utilization of common chronic-use medica-
tions and generalized all-causemedical services and costs pre- to post-diagnosis in
a real-world diverticulitis (DV) population.METHODS: Insurance claims from 40
US health plans representing 50 million lives were retrospectively analyzed. In-
clusion criteria were: primary diagnosis of colonic DV (ICD-9 562.11, 562.13) be-
tween January 1, 2005 and December 31, 2008; antibiotic within 3 days post-diag-
nosis; 12 months pre- and post-diagnosis enrollment. Use of non-GI-related
medications, as well as overall all-cause utilization and costs (2009 US$), were
descriptively evaluated pre- to post-diagnosis. All-cause costs were also evaluated
for non-DV controls matched 2:1 on age, gender, and plan enrollment, with index
date assigned as diagnosis date of each respective DV match. RESULTS: A total of
25,172 patients met all inclusion criteria (51.2% male, mean age 53 years). The top
5 most prevalent chronic-use medications during pre-index were antihyperlipi-
demics (30.0% of patients), antihypertensives (27.5%), antidepressants (20.9%), der-
matologicals (20.0%) and beta blockers (15.7%). Post-index use of thesemedications
increased by 8.9%, 8.2%, 7.3%, 9.1%, and 11.7%, respectively (all P0.010). Mean
all-cause hospital days and costs per patient increased significantly pre- to post-
index (0.9 vs. 2.3 days, $3223 vs. $6341; all P0.010). Other significant (P0.010)
increases pre- to post-index were seen for ER visits (0.7 vs. 1.2; $432 vs. $1012),
prescriptions (22 vs. 27 fills, $1910 vs. $2081), office visits (10 vs. 12, $1747 vs. $2251),
and other outpatient/specialty consultations (3 vs. 5, $2676 vs. $4288) (all P0.010).
Total all-cause costs increased by 60%post-diagnosis ($10,419 vs. $16,672; P0.010).
Minimal change occurred for controls ($6299 vs. $6493; P0.010). CONCLUSIONS:
Patients with DV have higher use of common chronic-use prescriptions after diag-
nosis, as well as significantly higher use and costs of general all-cause medical
services. Payers should be aware of increased costs for not only disease-related
services, but also other general health care.
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OBJECTIVES: Clostridium difficile-associated disease (CDAD) is a nosocomial gas-
trointestinal infection that has been associated with increases in health care costs.
Fidaxomixin was recently approved for CDAD but is costly compared to conven-
tional agents. We evaluated the cost-effectiveness of fidaxomicin, metronidazole,
and vancomycin in the treatment of CDAD.METHODS: A decision analysis model
was created to estimate the cost-effectiveness of fidaxomicin, metronidazole, and
vancomycin in clinical cure from the US health care payer perspective. Parameters
for the model were determined from the published literature and indirect treat-
ment comparison was performed using Bayesian methods to obtain the probabil-
ities for responder and recurrence rates. Medication costs were determined from
the AWP and resource costs were determined fromCPT and HCPCS codes. All costs
were adjusted for 2011 US dollars. Probabilities of responder and recurrence, costs,
and resource utilization were fitted with a beta, gamma, and triangle distribution,
respectively. Probabilistic sensitivity analysis with 10,000 trial simulations was
performed to test the robustness of the model. Probabilities of cost-effectiveness
for different treatment strategieswere plotted on a cost-effectiveness acceptability
frontier (CEAF). RESULTS: The total direct costs for fidaxomicin, metronidazole,
and vancomycin were $14,219.98, $13,927.53, and $13,554.08, respectively. The
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cost-effectiveness ratio for the treatment of CDAD with fidaxomicin, metronida-
zole, and vancomycin were $16,903.12, $20,229.74, and $17,386.62 per clinical cure,
respectively. Metronidazole was dominated by vancomycin. According to the
CEAF, vancomycin has a cost-effectiveness probability of 0.4 at a WTP of $0/addi-
tional cure. At a WTP $22,000/additional cure, however,fidaxomicin was more
cost-effective. CONCLUSIONS: Fidaxomicin is cost-effective when the WTP is
$22,000/additional cure. At a WTP $22,000/additional cure, however, vancomy-
cin is more cost-effective. Metronidazole does not appear to be a cost-effective
strategy for CDAD when compared to fidaxomicin and vancomycin.
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OBJECTIVES: Evaluate the cost-effectiveness of proton pump inhibitors (PPIs) avail-
able in the public health sector in Mexico for the treatment of gastroesophageal
Reflux Disease (GERD) graded C to D according to Los Angeles classification.
METHODS: A decision-analytic model was developed to estimate costs and effects
for each PPI (esomeprazole 40mg [ESO]; omeprazole 20mg [OME]; lansoprazole
30mg [LAN]; pantoprazole 40mg [PAN]). It was established a 4 weeks treatment
period, after it the patient heal rate was evaluated, and if the prescribed dose was
increased ormaintained. The relapse rate was also taken in account. The effective-
nessmeasurewas the proportion of patientswith endoscopic healing of the lesions
of the disease, using published data on effectiveness (healing and relapse rates) in
GERD. To estimate the resources consumption for diagnosis and treatment at dif-
ferent stages physician survey was carried out in August 2011 involving 7 gastro-
enterologists. Drug costs and health information comes from public health insti-
tutions. All costs were calculated in 2011 US Dollars (exchange rate in december
2011 1USD13.94 mexican pesos, source: http://www.banxico.org.mx). Univariate
sensitivity analysis was performed for the key variables of the model. RESULTS:
ESO was most effective than others comparators and resulted the alternative with
less unitary average total cost. ESO had a 99.6% heal rate and at a cost of $986.59
USD , OME had a 97% heal rate and a cost of $1140.77, PAN had a 94%heal rate and
a cost of $1456.74; LAN had a 98% of heal rate $1486.71. ESO is a dominant option
and cost saving compared to the alternatives. Deterministic probabilistic sensitiv-
ity analysis showed that the findings are robust.CONCLUSIONS:With these results
we can conclude that ESO is the dominant alternative, considering the total direct
medical costs. Esomeprazole provide better clinical efficacy at lower cost.
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OBJECTIVES: Many patients infected with HCV genotype 1 (HCVG1) have not re-
sponded to therapy with peginterferon plus ribavirin (PR). In May 2011, the Brazil-
ian Ministry of Health released guidelines for the treatment of patients with hep-
atitis C infection where the recommended retreatment regimen for HCVG1
infected patients is standard dose PR for 72 weeks. The extended compared to
standard treatment duration improves sustained virologic response (SVR) rates in
these patients. The aim of this study is to assess the cost effectiveness of this
improved efficacy.METHODS:We developed a Markov model to describe the clin-
ical history of HCV infection inwhich cohorts of HCVG1 previously treated patients
who didn’t achieve sustained response receives standard dose PR for 48 or 72
weeks. Patients with detectable HCV RNA level at week 12 have their treatment
interrupted. The patients are followed for their expected lifetime. The reference
patient is 30-year-old with CHC without cirrhosis. The SVRs to 48 and 72 weeks
cohorts came from RESPOND 2 and Jenssen DM et al, 2009 studies, respectively.
Quality of life for each health state was based on literature. Costs for each health
state were based on three Delphi panels (hepatologists, intensivists and oncolo-
gists). Costs in 2011 Brazilian Reais (BRL) and benefits were discounted at 3%.
RESULTS: The 72 weeks extended treatment increases life expectancy by 0.62 year
and quality adjusted life years (QALY) by 0.95 year compared to standard treament.
The incremental cost per life year gained is 3.423 BRL and the incremental cost per
QALY is 2.232 BRL. CONCLUSIONS: New drugs in development may further im-
prove retreatment options, but until then the Brazilian Ministry of Health recom-
mendation to extend the treatment to 72 weeks in HCV genotype 1 previously
treated patients who didn’t achieve sustained response is cost-effective as com-
pared with standard 48 weeks duration.
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OBJECTIVES: In patients with chronic infection with hepatitis C virus (HCV) geno-
type 1 who do not have a sustained response to the standard therapy with pegin-
terferon-ribavirin (PR) the treatment with the combination of boceprevir plus
peginterferon alfa/ribavirin (BPR) has been shown to produce a higher rate of sus-
tained virological response (SVR) than the retreatment with PR. The aim of this
study is to assess the cost effectiveness of this improved efficacy. METHODS: We
developed a Markov model to describe the clinical history of HCV infection in
which HCV genotype 1 previously treated patients who did not achieve sustained
response receives PR for 4 weeks and subsequently, one cohort (A) receives PR for
44 weeks and another cohort (B) receives BPR for 32 weeks and, in this cohort (B),
those patients with a detectable HCV RNA level at week 8 receives PR for an addi-
tional 12 weeks. All patients are followed for their expected lifetime. The reference
patient is 30-year-old with CHC without cirrhosis. The SVRs to BPR and PR cohorts
came from RESPOND 2 study. Quality of life for each health state was based on
literature. Costs for each health state were based on three Delphi panels, one with
hepatologists, one with intensivists and another with oncologists. Costs in 2011
Brazilian Reais and benefitswere discounted at 3%.RESULTS:The combination BPR
increases life expectancy by 2.75 years and quality adjusted life years (QALY) by
4.19 years compared to PR. The incremental cost per life year gained is 7.992 Bra-
zilian Reais and the incremental cost per QALY is 5.244 Brazilian Reais.
CONCLUSIONS: In Brazil, boceprevir plus peginterferon alfa/ribavirin is a cost-
effective therapy, for the treatment of previously treated patients with HCV geno-
type 1 infection as compared with peginterferon alfa/ribavirin alone.
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OBJECTIVES: In previously untreated adults with hepatitis C virus (HCV) genotype
1 infection the combination of boceprevir plus peginterferon alfa/ribavirin (BPR)
has been shown to produce a higher rate of sustained virological response (SVR)
than peginterferon alfa/ribavirin (PR). The aim of this study is to assess the cost
effectiveness of this improved efficacy.METHODS:We developed a Markov model
to describe the clinical history of CHC inwhichHCV genotype 1 patients receives PR
for 4 weeks and subsequently one cohort (A) receives PR for 44 weeks and another
cohort (B) receives BPR for 24 weeks and, in this cohort (B), those patients with a
detectable HCV RNA level between weeks 8 and 24 receives PR for an additional 20
weeks. All patients are followed for their expected lifetime. The reference patient is
30-year-oldwith CHCwithout cirrhosis. The SVRs to BPR and PR cohorts came from
SPRINT 2 study. Quality of life for each health state was based on literature. Costs
for each health state were based on three Delphi panels, one with hepatologists,
one with intensivists and another with oncologists. Costs in 2011 Brazilian Reais
and benefitswere discounted at 3%.RESULTS:BPR increases life expectancy by 2.07
years and quality adjusted life years (QALY) by 3.15 years compared to PR. The
incremental cost per life year gained is 11.394 Brazilian Reais and the incremental
cost per QALY is 7.494 Brazilian Reais. CONCLUSIONS: In Brazil, boceprevir plus
peginterferon alfa/ribavirin is a cost-effective therapy, for treatment of previously
untreated adults with HCV genotype 1 compared with peginterferon alfa/ribavirin.
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OBJECTIVES: Although the incidence of diverticulitis (DV) is increasing and DV
attacks are common, resource utilization associated with DV inpatient admissions
has not been extensively analyzed. To better understand the economic burden of
DV, detailed chart reviews were performed to quantitate resource utilization in a
random sample of DV admissions at a VA medical center from 1996 to 2010.
METHODS:We examined clinical variables and resource counts including surgical
and gastrointestinal consults, computerized tomography scans, laboratory values,
interventional radiology (IR) procedures, surgeries, medications, length of stay
(LOS), and intensive care unit (ICU), monitored bed, and ward days. Resource mi-
cro-costing from a third-party payer perspective was performed based on 2010
Current Procedural Terminology fees and the Red Book. Aggregate costs for initial
and subsequent attacks were compared and cost predictors were identified by
multivariable regression. RESULTS:Among 240 patients (age, 66.6 years; 95%male)
with complete data, themean (standard deviation [SD]) LOS per admissionwas 10.4
(20.66) days with a mean (SD) of 1.2 (4.19), 1.7 (4.35), and 6.0 (9.03) days in ICU,
monitored, and ward beds, respectively. Patients’ mean maximum temperature
(Tmax) and white blood cell count were 99.7° F and 14.7K, respectively; 29% re-
ceived surgery and 11% received IR procedures. Mean (SD) and median costs per
admission were $8496 ($14,002) and $4,080, respectively. An upward trend in me-
dian cost was observed for first, second, and subsequent admissions ($3707, $4722,
and $6143 per stay, respectively; not statistically significant). LOS was indepen-
dently associated with increasing patient age, higher Tmax, and receipt of surgery
(P0.0001 for all; R2 47%). CONCLUSIONS: These findings describe the economic
burden of DV and identify clinical parameters that may be associated with in-
creased resource utilization. Future studies will be needed to determine if these
benchmarks are consistent in other and/or larger populations.
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